Abstract 08: Efficacy and Safety of the Selective Aldosterone Synthase Inhibitor Lorundrostat in Moderate-to-Severe Obstructive Sleep Apnea and Hypertension: Explore-OSA Randomized Crossover Trial
Hypertension · 2026-10 · 83 (Suppl_1)
DOI: 10.1161/hyp.83.suppl_1.08 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hypertension, 2026-10. Verfasst von Reena Mehra und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction: Uncontrolled hypertension (uHTN), a major driver of adverse cardiovascular (CV) outcomes, affects up to 80% of patients with obstructive sleep apnea (OSA). While established OSA therapies such as positive airway pressure (PAP), hypoglossal nerve stimulation, and mandibular advancement devices can effectively restore upper airway patency, their effect on systolic blood pressure (SBP) reduction is generally modest (
Zitieren
APA
Mehra, R., Kopjar, B., Rodman, D., & Laffin, L. J. (2026). Abstract 08: Efficacy and Safety of the Selective Aldosterone Synthase Inhibitor Lorundrostat in Moderate-to-Severe Obstructive Sleep Apnea and Hypertension: Explore-OSA Randomized Crossover Trial. Hypertension, 83(Suppl_1). https://doi.org/10.1161/hyp.83.suppl_1.08
Vancouver
Mehra R, Kopjar B, Rodman D, Laffin LJ. Abstract 08: Efficacy and Safety of the Selective Aldosterone Synthase Inhibitor Lorundrostat in Moderate-to-Severe Obstructive Sleep Apnea and Hypertension: Explore-OSA Randomized Crossover Trial. Hypertension. 2026;83(Suppl_1). doi:10.1161/hyp.83.suppl_1.08
BibTeX
@article{Mehra2026,
author = {Mehra, Reena and Kopjar, Branko and Rodman, David and Laffin, Luke J},
title = {Abstract 08: Efficacy and Safety of the Selective Aldosterone Synthase Inhibitor Lorundrostat in Moderate-to-Severe Obstructive Sleep Apnea and Hypertension: Explore-OSA Randomized Crossover Trial},
journal = {Hypertension},
year = {2026},
volume = {83},
number = {Suppl_1},
doi = {10.1161/hyp.83.suppl_1.08}
}
EUVIMED